{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-24-000137","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.889062+00:00","generated_at":"2026-06-06T19:09:00.234668+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"Lexaria CEO provides 2024 outlook; GLP-1 pilot shows DehydraTECH semaglutide benefit; IND filing imminent","bullets":["Stock recovered above $1, avoiding reverse split; October capital raise on less punitive terms.","DehydraTECH semaglutide pilot (7 subjects) showed statistically higher drug proportion, faster absorption, fewer side effects vs Rybelsus.","FDA IND application for hypertension delayed ~5 months due to supplier; submission expected soon.","No debt taken in 2023 and no plan for debt in 2024; institutional holders rose to 19 with 1.8M shares.","R&D highlights: catestatin, inflammatory biomarkers, weight loss, blood glucose reduction, and nicotine study beating Zyn/On."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-24-000137","json":"https://secwatch.observer/filing/0001640334-24-000137.json","markdown":"https://secwatch.observer/filing/0001640334-24-000137.md","text":"https://secwatch.observer/filing/0001640334-24-000137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000137/0001640334-24-000137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000137/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T19:09:00.234668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}